# Colorectal Cancer Screening: Modalities and Strategies

## Overview

Colorectal cancer (CRC) is the third most common cancer and second leading cause of cancer death in the U.S. (~53,000 deaths/year) Incidence and mortality have declined ~30% since mid-1990s, largely due to screening and polyp removal. Screening detects precancerous polyps (adenomas, sessile serrated lesions) allowing cancer prevention, not just early detection. USPSTF recommends screening all average-risk adults ages 45-75 (A recommendation) and selectively 76-85 (C recommendation) Multiple screening modalities are available; the best test is the one the patient will complete. Rising incidence in adults <50 prompted lowering of screening start age from 50 to 45.

## Epidemiology

### Incidence and Mortality

~153,000 new CRC cases and ~53,000 deaths annually in the U.S. Lifetime risk: ~4% (1 in 23) Higher incidence and mortality in non-Hispanic Black adults, American Indian/Alaska Native populations. Geographic: higher rates in Appalachia, Southeast, and rural areas. CRC mortality has declined ~55% since peak in the 1980s.

### Rising Incidence in Young Adults

CRC incidence in adults <50 has increased ~2% per year since the mid-1990s. Now the leading cause of cancer death in men <50 and second in women <50. Disproportionately affects millennials and Gen X; rectal cancer increasing faster than colon cancer. Contributing factors (under investigation): obesity, sedentary behavior, ultra-processed diets, microbiome changes, environmental exposures. Prompted USPSTF (2021), ACS (2018), and other organizations to lower screening start age to 45.

### Risk Factors

Average risk: age >=45 with no additional risk factors. Increased risk: personal history of adenomatous polyps, personal history of CRC, first-degree relative with CRC or advanced adenoma, inflammatory bowel disease (UC, Crohn's colitis) High risk (hereditary syndromes): Lynch syndrome (HNPCC), familial adenomatous polyposis (FAP), attenuated FAP, MUTYH-associated polyposis, Peutz-Jeghers, juvenile polyposis. Modifiable: obesity, physical inactivity, red/processed meat, alcohol, tobacco.

## Screening Modalities

### Stool-Based Tests

#### Fecal Immunochemical Test (FIT)

Detects human hemoglobin in stool using antibodies. Annual testing recommended. Sensitivity for CRC: ~74-79% (single test); increases with annual testing. Specificity: ~94-96%. No dietary or medication restrictions (unlike older guaiac FOBT) Advantages: non-invasive, inexpensive (~$20), no bowel prep, done at home. Programmatic FIT: mailed kits with reminders improve participation rates. Positive FIT requires colonoscopy follow-up (critical; ~50% of patients with positive FIT fail to complete follow-up colonoscopy)

#### FIT-DNA (Cologuard)

Multi-target stool DNA test combining FIT with molecular markers (KRAS, NDRG4, BMP3 methylation) Every 3 years. Sensitivity for CRC: ~92%; sensitivity for advanced adenomas: ~42%. Specificity: ~87% (lower than FIT alone, meaning more false positives) Higher sensitivity but lower specificity than FIT; cost ~$600. Positive test requires colonoscopy follow-up. False positives more common; management of false-positive results can generate anxiety and unnecessary procedures.

### Direct Visualization

#### Colonoscopy

Gold standard for both detection and simultaneous polypectomy. Every 10 years for average risk (if normal) Sensitivity for CRC: ~95%; sensitivity for adenomas >=10 mm: ~95%. Requires bowel preparation and (usually) sedation. Risks: perforation (~4/10,000), bleeding (~8/10,000 for polypectomy), sedation-related complications. Quality dependent on adenoma detection rate (ADR): minimum threshold >=25% overall (>=30% for men, >=20% for women); higher ADR associated with lower interval CRC rates. Completion of follow-up colonoscopy after positive stool test is a critical quality metric.

#### CT Colonography (Virtual Colonoscopy)

CT-based imaging of the colon with air insufflation. Every 5 years. Sensitivity for polyps >=10 mm: ~90%; sensitivity for polyps 6-9 mm: ~70-80%. No sedation required but requires bowel prep. Extracolonic findings: detected in ~40-70% of exams (may lead to additional workup, cost, anxiety) Not widely covered by all insurers; limited availability.

#### Flexible Sigmoidoscopy

Examines distal colon (rectum through splenic flexure) Every 5 years (alone) or every 10 years with annual FIT. RCT evidence: 26-31% reduction in CRC mortality (PLCO, UK Flexible Sigmoidoscopy trials) Misses proximal (right-sided) cancers; declining use in the U.S. Does not require sedation; limited bowel prep.

| Modality | Interval | Sensitivity for CRC | Specificity | Key Advantage | Key Limitation |
|---|---|---|---|---|---|
| FIT | Annual | 74-79% (single) | 94-96% | Non-invasive, cheap, no prep | Requires annual adherence; misses some adenomas |
| FIT-DNA (Cologuard) | Every 3 years | ~92% | ~87% | High CRC sensitivity | More false positives; cost ~$600 |
| Colonoscopy | Every 10 years | ~95% | ~95% | Detection + polypectomy in one | Bowel prep, sedation, perforation risk |
| CT colonography | Every 5 years | ~90% (polyps ≥10mm) | High | No sedation | Requires bowel prep; extracolonic findings |
| Flex sigmoidoscopy | Every 5 years | Distal colon only | High | No sedation, limited prep | Misses proximal cancers |
| Flex sig + annual FIT | Every 10 years | Combined coverage | Combined | Complements distal + proximal detection | Two-test burden |

### Blood-Based Tests (Emerging)

#### Cell-Free DNA (cfDNA) / Liquid Biopsy

Shield (Guardant Health): blood test detecting CRC-associated cfDNA methylation patterns. FDA-approved 2024 for average-risk CRC screening. Sensitivity for CRC: ~83%; sensitivity for advanced adenomas: ~13%. Specificity: ~90%. Advantages: simple blood draw, high patient acceptance. Limitations: significantly lower sensitivity for precancerous lesions (adenomas) than colonoscopy or FIT. Role: may increase screening participation among those who refuse stool tests or colonoscopy; positioned as complement, not replacement.

## The NordICC Trial and Colonoscopy Debate

European RCT (N=84,585): invitation to colonoscopy screening vs. usual care. Intention-to-treat analysis: 18% reduction in CRC incidence, no significant reduction in CRC mortality at 10 years. Per-protocol analysis (among those who actually underwent colonoscopy): 31% incidence reduction, 50% mortality reduction. Interpretation controversy: does colonoscopy screening have less benefit than assumed? Key caveats: only 42% of invited group underwent colonoscopy; 10-year follow-up may be too short for mortality benefit; European endoscopy quality/ADR may differ from U.S. practice. Does not undermine colonoscopy as a diagnostic follow-up for positive stool tests.

## Guideline Comparison

### USPSTF (2021)

Ages 45-75: screen (A recommendation); ages 76-85: selective (C) No preferred modality; options include colonoscopy (q10y), FIT (annual), FIT-DNA (q3y), CT colonography (q5y), flexible sigmoidoscopy (q5y or q10y with annual FIT)

### ACS (2018)

Ages 45-75: regular screening; ages 76-85: individualized; 85+: discontinue. Colonoscopy and FIT as top-tier options.

### ACG (2021)

Colonoscopy every 10 years as preferred screening test. FIT annually as preferred non-invasive alternative.

<image>A comparison table of CRC screening modalities showing: test name, interval, sensitivity for CRC, sensitivity for advanced adenomas, specificity, advantages, disadvantages, and approximate cost. Modalities include: annual FIT, FIT-DNA (q3y), colonoscopy (q10y), CT colonography (q5y), flexible sigmoidoscopy (q5y), and blood-based cfDNA (Shield). Color-coded to distinguish stool-based, direct visualization, and blood-based categories. CRC screening modalities education illustration.</image>

<image>A graph showing U.S. colorectal cancer incidence trends from 1990 to 2024 for two age groups: adults >=50 (declining trend) and adults <50 (increasing trend). The diverging trends are annotated with key milestones: widespread colonoscopy adoption in the 2000s (contributing to decline in older adults) and the 2021 USPSTF recommendation to begin screening at age 45. Early-onset CRC education illustration.</image>

<image>A flowchart showing the CRC screening decision pathway for average-risk adults: starting at age 45, choosing a modality (FIT, FIT-DNA, colonoscopy, etc.), then showing follow-up pathways for positive stool tests (mandatory colonoscopy) and colonoscopy findings (surveillance intervals based on polyp number, size, and histology). The critical gap in follow-up colonoscopy completion after positive FIT (~50% non-completion) is highlighted as a quality concern. CRC screening pathway education illustration.</image>

## Clinical Pearls

The best CRC screening test is the one the patient will complete -- programmatic mailed FIT with reminders achieves higher population participation rates than colonoscopy-only strategies. Failure to complete colonoscopy after a positive FIT is a major quality gap -- approximately 50% of patients with a positive stool test do not complete timely follow-up colonoscopy, negating the benefit of screening. The NordICC trial does not prove colonoscopy is ineffective -- the 42% compliance rate in the invited group diluted the intention-to-treat result; per-protocol analysis showed significant benefit. Blood-based screening (Shield) has poor sensitivity for precancerous adenomas (~13%) -- it may increase participation but should not replace stool tests or colonoscopy for those willing to complete them. For boards: know FIT vs. FIT-DNA performance characteristics, colonoscopy quality metrics (ADR >=25%), the rising incidence in adults <50, and the USPSTF age thresholds (45-75 A, 76-85 C)

## References

- USPSTF. Screening for colorectal cancer. JAMA. 2021;325(19):1965-1977.
- Bretthauer M, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death (NordICC). N Engl J Med. 2022;387(17):1547-1556.
- Imperiale TF, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
- Siegel RL, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109(8):djw322.
- Chiu HM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality. Gut. 2021;70(8):1567-1573.